Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

The New England journal of medicine

Survival Analysis, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, therapeutic use, Chemotherapy, Adjuvant, Colonic Neoplasms, drug therapy, mortality, pathology, surgery, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Humans, Leucovorin, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, Proportional Hazards Models

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival. A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer. Copyright 2004 Massachusetts Medical Society

      Related collections

      Author and article information

      Journal
      10.1056/NEJMoa032709
      15175436

      Comments

      Comment on this article